Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 26, 2023 07:00 ET | Source: Oculis SA

Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs

Oculis establishes its US headquarters in Boston, MA, a world-renowned biotech hub, to support its continued expansion following OCS listing into NASDAQ Oculis’s finance and development team...
April 05, 2023 07:00 ET | Source: Oculis SA

Oculis to Participate at Upcoming Investor Conferences

ZUG, Switzerland and BOSTON, April 05, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
April 04, 2023 07:00 ET | Source: Oculis SA

Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
March 22, 2023 07:00 ET | Source: Oculis SA

Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing

ZUG, Switzerland, and BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye...
March 16, 2023 09:45 ET | Source: Oculis SA

Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial

Completed enrollment in Phase 3 OPTIMIZE trial brings OCS-01 one step further on the regulatory path to approval.If approved, OCS-01 has the potential to become the first once-daily, topical,...
September 01, 2020 08:00 ET | Source: Oculis SA

Oculis establishes presence in U.S. and appoints Sylvia Cheung as Chief Financial Officer

LAUSANNE, Switzerland, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives...
April 21, 2020 08:00 ET | Source: Oculis SA

Oculis Appoints Dr. Frédéric Pilotaz as Vice President of Technology & Pharmaceutical Sciences

LAUSANNE, Switzerland, April 21, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic...
March 03, 2020 08:00 ET | Source: Oculis SA

Oculis Appoints Marcia de Souza Lima, M.D., as Chief Medical Officer

LAUSANNE, Switzerland, March 03, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic...
February 10, 2020 08:00 ET | Source: Oculis SA

Oculis Announces Positive OCS-01 Phase 2 Data in Patients with Diabetic Macular Edema (DME)

OCS-01 is a proprietary topical nanoparticle formulation of dexamethasone that has the potential to treat retinal diseases The Phase 2 (DX-211) study provides a clinical proof-of-concept of OCS-01...
January 22, 2020 08:00 ET | Source: Oculis SA

Oculis Announces Upcoming Presentation of Phase 2 Data of OCS-01 in Patients with Diabetic Macular Edema (DME) at Angiogenesis, Exudation, and Degeneration 2020

LAUSANNE, Switzerland, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic...